Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$8.36
+0.4%		$7.76
$2.71
▼
$10.31
$376.20M1.311.11 million shs1.09 million shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$48.53
-0.2%		$55.04
$19.65
▼
$72.36
$1.45B0.76573,517 shs441,119 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$96.99
-1.0%		$102.78
$28.16
▼
$155.29
$1.44B3.82351,424 shs201,446 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$4.63
-2.3%		$5.62
$3.69
▼
$7.30
$1.54B1.194.04 million shs2.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
+0.36%-2.11%+3.34%+139.54%+114.36%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-0.21%-4.84%-13.09%-23.48%+51.80%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-0.96%-2.63%-22.39%-0.60%+185.43%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-2.32%-0.86%-17.91%-29.10%+45.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$8.36
+0.4%		$7.76
$2.71
▼
$10.31
$376.20M1.311.11 million shs1.09 million shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$48.53
-0.2%		$55.04
$19.65
▼
$72.36
$1.45B0.76573,517 shs441,119 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$96.99
-1.0%		$102.78
$28.16
▼
$155.29
$1.44B3.82351,424 shs201,446 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$4.63
-2.3%		$5.62
$3.69
▼
$7.30
$1.54B1.194.04 million shs2.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
+0.36%-2.11%+3.34%+139.54%+114.36%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-0.21%-4.84%-13.09%-23.48%+51.80%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-0.96%-2.63%-22.39%-0.60%+185.43%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-2.32%-0.86%-17.91%-29.10%+45.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.50
Moderate Buy$24.50193.06% Upside
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.71
Moderate Buy$77.7960.28% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$197.50103.63% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$12.77175.79% Upside

Current Analyst Ratings Breakdown

Latest AGEN, ANAB, TSHA, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$70.00 ➝ $60.00
9/28/2026
Agenus Inc. stock logo
AGEN
Agenus
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$19.00
9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$90.00 ➝ $81.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/18/2026
Agenus Inc. stock logo
AGEN
Agenus
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/17/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/11/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/31/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$78.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$114.20M3.31N/AN/A($8.17) per share-1.02
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$232.39M6.24N/AN/A$1.34 per share36.22
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/A$0.55 per shareN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$5.49M275.04N/AN/A$0.90 per share5.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
$120K$2.583.24N/AN/A69.33%-47.68%57.73%11/9/2026 (Estimated)
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$5.379.0440.78N/A82.37%112.00%2.20%11/3/2026 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.88N/AN/AN/AN/A-563.90%-83.48%11/13/2026 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$109M-$0.42N/AN/AN/AN/A-56.19%-41.84%11/3/2026 (Estimated)

Latest AGEN, ANAB, TSHA, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/13/2026Q2 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.28-$2.34-$0.06-$2.34N/AN/A
8/11/2026Q2 2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.1133-$0.13-$0.0167-$0.13$0.68 millionN/A
8/7/2026Q2 2026
Agenus Inc. stock logo
AGEN
Agenus
$0.05-$0.01-$0.06-$0.01$34.00 million$34.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.34
0.34
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
5.07
5.07
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.13
17.76
17.76

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
6.50%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
8145.16 million42.23 millionOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.90 million20.48 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
11014.72 million12.03 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
99325.83 million314.50 millionOptionable

Recent News About These Companies

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 2 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373768/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
October 1 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372824/0/en/taysha-gene-therapies-announces-multiple-encore-presentations-supporting-tsha-102-rett-syndrome-clinical-program-at-the-55th-child-neurology-society-annual-meeting.html
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-taysha-gene-therapies-nasdaq-tsha-shares-up-57-heres-what-happened-2026-09-28/
Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-taysha-gene-therapies-nasdaq-tsha-earns-outperform-rating-from-analysts-at-wolfe-research-2026-09-17/
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-taysha-gene-therapies-inc-nasdaq-tsha-receives-average-recommendation-of-buy-from-analysts-2026-09-12/
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945540-taysha-gene-therapies-a-bull-case-that-does-not-require-the-fastest-approval
Illustration of an industrial facility with a glowing upward arrow chart line overlaid against a city skyline at dusk.
These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)
...
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/these-3-risky-stocks-could-be-sitting-on-100-upside/
Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-acquires-3349244-shares-of-taysha-gene-therapies-inc-tsha-2026-09-06/
Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-new-position-in-taysha-gene-therapies-inc-tsha-2026-09-06/
Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-has-994-million-holdings-in-taysha-gene-therapies-inc-tsha-2026-09-05/
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356521/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Taysha Gene Therapies Earnings Call Highlights Pivotal Progress
August 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/taysha-gene-therapies-earnings-call-highlights-pivotal-progress?utm_source=marketbeat.com&utm_medium=referral
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-q2-231331648.html
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TSHA/pressreleases/3824580/wells-fargo-issues-a-buy-rating-on-taysha-gene-therapies-tsha/
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-rett-140937044.html
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69283092-taysha-gene-therapies-inc-taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-inc-tsha-050217398.html
Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4631192-taysha-outlines-reveal-6-month-interim-analysis-and-fda-feedback-in-h1-2027-while-targeting
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935110-taysha-gene-therapies-inc-tsha-q2-2026-earnings-call-transcript
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343130/0/en/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338769/0/en/taysha-gene-therapies-to-release-second-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-august-11.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Snowflake logo illuminated between server racks in a data center with a digital cloud graphic overhead.
Could Snowflake's Big Quarter Be a Sign of More to Come?
By Nathan Reiff | September 11, 2026
Illustration of an industrial facility with a glowing upward arrow chart line overlaid against a city skyline at dusk.
These 3 Risky Stocks Could Be Sitting on 100% Upside
By Nathan Reiff | September 7, 2026
Snowflake logo displayed against a digitally rendered background of illuminated data server towers and snow.
Snowflake’s AI Momentum Is Forcing a Fresh Look at the Stock
By Thomas Hughes | September 4, 2026
AST SpaceMobile logo displayed over a rendered satellite orbiting Earth with a network diagram.
AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
By Jessica Mitacek | September 11, 2026
Microsoft logo displayed on a wall between rows of illuminated server racks in a data center.
Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
By Chris Markoch | September 11, 2026
Agenus stock logo

Agenus NASDAQ:AGEN

$8.36 +0.03 (+0.36%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$8.38 +0.02 (+0.24%)
As of 10/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$48.53 -0.10 (-0.21%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$48.58 +0.05 (+0.09%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$96.99 -0.94 (-0.96%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$97.10 +0.12 (+0.12%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$4.63 -0.11 (-2.32%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.64 +0.01 (+0.32%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas